SCHEDULE: Point72 Reduces Stake in Replimune Group to 4.7%

Point72 Asset Management, along with Point72 Capital Advisors Inc. and Steven A. Cohen, has reported a beneficial ownership of 4.7% in Replimune Group, Inc. common stock.

Summary

• Point72 Asset Management, L.P., Point72 Capital Advisors, Inc., and Steven A. Cohen collectively beneficially own 3,629,902 shares of Replimune Group, Inc. common stock.
• This ownership represents 4.7% of the issuer's class of securities.
• The reporting persons hold shared voting power and shared dispositive power over all 3,629,902 shares.
• No sole voting or dispositive power is held by any individual reporting person.
• The filing is an Amendment No. 1 to a Schedule 13G, indicating a change from a previous filing, with the current stake falling below the 5% threshold.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to the reduction in a significant institutional investor's stake below the 5% reporting threshold, which can be perceived as a lack of conviction or a strategic exit.

Positives

• NA

Negatives

• The reduction in Point72's stake to below 5% could be interpreted as a decrease in conviction or a reallocation of capital by a significant institutional investor.

Risks

• NA

Future Outlook

This filing does not contain any forward-looking statements or guidance from the issuer.

Management Comments

• Point72 Asset Management, Point72 Capital Advisors Inc., and Mr. Cohen certify that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer, nor in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under Rule 14a-11.

Industry Context

This filing reflects a change in an institutional investor's position in a biotechnology company, which is a common occurrence in the dynamic investment landscape. It does not provide broader industry trends or competitive analysis.

Stakeholder Impact

• Shareholders: The reduction in a significant institutional investor's stake could influence investor sentiment and potentially the stock price, as it may signal a change in institutional confidence in Replimune Group, Inc.

Key Dates

Keywords

Replimune Group, Point72 Asset Management, Steven A. Cohen, Beneficial Ownership, Schedule 13G, Common Stock, Institutional Investor, Equity Stake